Metagenomi, Inc. (NASDAQ:MGX) Receives Average Recommendation of “Moderate Buy” from Analysts

Metagenomi, Inc. (NASDAQ:MGX) has been given an average recommendation of “Moderate Buy” by the five brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $10.00.

A number of research analysts have weighed in on MGX shares. Wall Street Zen lowered Metagenomi from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Metagenomi in a report on Monday, December 22nd.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets raised its position in shares of Metagenomi by 1,840.0% in the third quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company’s stock worth $36,000 after buying an additional 14,389 shares in the last quarter. Bank of America Corp DE boosted its stake in Metagenomi by 508.5% during the third quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock valued at $44,000 after buying an additional 15,682 shares during the period. Panagora Asset Management Inc. purchased a new position in Metagenomi during the fourth quarter worth about $53,000. Quadrature Capital Ltd purchased a new position in Metagenomi during the fourth quarter worth about $55,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Metagenomi in the 3rd quarter worth about $64,000.

Metagenomi Price Performance

Metagenomi stock opened at $1.39 on Friday. The firm has a market capitalization of $52.29 million, a P/E ratio of -0.59 and a beta of 0.45. Metagenomi has a one year low of $1.23 and a one year high of $3.95. The business has a fifty day moving average price of $1.53 and a 200-day moving average price of $1.89.

Metagenomi (NASDAQ:MGX) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). The company had revenue of $3.91 million for the quarter, compared to the consensus estimate of $7.33 million. Metagenomi had a negative net margin of 348.54% and a negative return on equity of 47.14%. Sell-side analysts expect that Metagenomi will post -2.46 earnings per share for the current fiscal year.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.